Abstract
Antitumour necrosis factor alpha agents are important treatments in many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis and the inflammatory bowel diseases. However, there have been case reports of optic neuritis and other demyelinating diseases as complications of these agents. This case report presents a patient with ulcerative colitis on infliximab who presented with sudden onset mono-ocular visual field loss and highlights the diagnosis and management of infliximab-induced optic neuritis.
Keywords:
biological agents; drugs: CNS (not psychiatric); inflammatory bowel disease; neuroopthalmology; visual pathway.
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Blindness / diagnosis
-
Blindness / drug therapy
-
Blindness / immunology*
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / immunology
-
Drug Substitution
-
Gastrointestinal Agents / adverse effects*
-
Humans
-
Infliximab / adverse effects*
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Optic Nerve / diagnostic imaging
-
Optic Nerve / drug effects
-
Optic Nerve / immunology
-
Optic Neuritis / complications
-
Optic Neuritis / diagnosis
-
Optic Neuritis / drug therapy
-
Optic Neuritis / immunology*
-
Prednisolone / therapeutic use
-
Tomography, Optical Coherence
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / immunology
-
Visual Acuity
-
Visual Field Tests
-
Visual Fields
Substances
-
Antibodies, Monoclonal, Humanized
-
Gastrointestinal Agents
-
TNF protein, human
-
Tumor Necrosis Factor-alpha
-
Prednisolone
-
vedolizumab
-
Infliximab